Dr. Bin Huang reports

EMERALD LAUNCHES MARKET LEADING CBD OIL AND SUPPORTS PROPOSED CANNABIS LEGISLATION

Emerald Health Therapeutics Inc. has launched its CBD-25 and CBD-50 medical cannabis oils containing 25 milligrams and 50 mg of cannabidiol (CBD) per millilitre. Management believes these oils contain the highest amount of CBD per ml, with a nominal amount of THC, on the access to cannabis for medical purposes regulations market today, putting Emerald in a leading position for CBD medical cannabis extracts, an important dosage form for patients and their doctors.

Emerald created these new products based on its continuing research to characterize cannabis strains and their attributes, which identified particularly high CBD cultivars optimal for CBD extraction. Emerald secured federal funding from the Canadian National Research Council's industrial research assistance program to support this research and is continuing to develop a product line with a high level of genetic and product diversity.

"These high CBD oils have minute amounts of THC and thus little to no psychoactive effects. Emerald is also actively developing capsules that will have the advantage of precise dosing in a format familiar to patients and doctors. We believe that capsules are the ideal form of delivery for patients with little or no experience with cannabis and will become the preferred delivery method in the medical cannabis industry," says Dr. Bin Huang, president and chief executive officer of Emerald. "We look forward to conducting clinical studies to assess the efficacy of our formulations in the management of medical conditions such as insomnia and pain."

Emerald supports proposed cannabis act

Emerald strongly supports the Canadian government's recently proposed legislation regarding the legalization of adult-use cannabis in Canada, a significant step toward the implementation of adult-use cannabis in Canada on or before July 1, 2018.

"Emerald supports the federal government's legislative initiative to legalize, regulate and restrict access to cannabis by the Canadian public. Legalization is a considerable undertaking that will touch all aspects of Canadian society and has the potential to be viewed around the world as the leading benchmark for adult-use cannabis regulated at a national level. As one of 43 licensed producers, we are pleased to see the federal government's recognition of good production practices and desire to establish an efficient cross-country cannabis market. We look forward to participating in the future adult-use cannabis industry and aim to offer consumers the same level of quality, consistency and experience that our current patients enjoy. Legalization would not only open the doors to general adult use of cannabis, but provide many consumers with the opportunity to explore the possible physiological effects of cannabis against conditions such as poor sleep and pain," said Dr. Avtar Dhillon, executive chairman of Emerald.

"In preparing to supply the adult-use cannabis market, we are rapidly expanding our cultivation space prior to legalized sales under the proposed regulatory framework. We are currently executing on phases 1 and 2 of our expansion plan, which combined will initially add 100,000 square feet of purpose-built hybrid greenhouse space on 32 acres of land in Metro Vancouver. With close to $40-million in the bank post our upsized financing with Eight Capital, Emerald is well capitalized for future growth."

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics operates primarily through Emerald Health Botanicals Inc., a wholly owned subsidiary of the company and a licensed producer under the access to cannabis for medical purposes regulations (the ACMPR). Botanicals is authorized to cultivate and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor cultivation facility in Victoria, B.C., and plans to construct a much larger purpose-built hybrid greenhouse facility on 32 acres in Metro Vancouver. Botanicals prides itself on being one of Canada's most medically focused licensed producers and on having one of the industry's most qualified management teams with respect to pharmaceutical drug discovery, development and distribution.

We seek Safe Harbor.